Silvant Capital Management’s Idexx Laboratories IDXX Stock Holding History

Silvant Capital Management’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.78M	Buy	16,682 +3,434	+26%	+$1.93M	0.26%	57
2026 Q1	$7.44M	Buy	13,248 +213	+2%	+$137K	0.26%	43
2025 Q4	$8.82M	Buy	13,035 +1,918	+17%	+$1.31M	0.3%	42
2025 Q3	$7.1M	Sell	11,117 -1,051	-9%	-$638K	0.25%	49
2025 Q2	$6.53M	Hold	12,168	–	–	0.25%	54
2025 Q1	$5.11M	Hold	12,168	–	–	0.24%	58
2024 Q4	$5.03M	Hold	12,168	–	–	0.21%	61
2024 Q3	$6.15M	Hold	12,168	–	–	0.27%	49
2024 Q2	$5.93M	Sell	12,168 -3,361	-22%	-$1.69M	0.26%	56
2024 Q1	$8.38M	Hold	15,529	–	–	0.4%	37
2023 Q4	$8.62M	Hold	15,529	–	–	0.46%	33
2023 Q3	$6.79M	Hold	15,529	–	–	0.41%	39
2023 Q2	$7.8M	Hold	15,529	–	–	0.44%	36
2023 Q1	$7.77M	Hold	15,529	–	–	0.51%	36
2022 Q4	$6.34M	Sell	15,529 -161	-1%	-$62.5K	0.45%	42
2022 Q3	$5.11M	Buy	+15,690	New	+$5.76M	0.35%	51

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Silvant Capital Management's IDXX Position: Q2 2026 in Review

Silvant Capital Management increased its Idexx Laboratories (IDXX) stake by 26% in Q2 2026, buying an estimated $1.93M and bringing the position to 16,682 shares worth $8.78M. The position accounts for 0.26% of the portfolio, ranked #57.

Silvant Capital Management first reported a position in IDXX in Q3 2022 and has held it in 16 quarters since. The position peaked at $8.82M in Q4 2025. 1,306 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

Silvant Capital Management held 16,682 shares of Idexx Laboratories worth $8.78M as of Q2 2026.
Silvant Capital Management bought 3,434 Idexx Laboratories shares in Q2 2026, an estimated $1.93M.
Idexx Laboratories made up 0.26% of Silvant Capital Management's portfolio in Q2 2026, its #57 holding.
Silvant Capital Management first reported a position in Idexx Laboratories in Q3 2022 and has held it in 16 quarters since.
Silvant Capital Management's Idexx Laboratories position peaked at $8.82M in Q4 2025.
1,306 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Silvant Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.